This roundtable series reflects on the management of patients with myeloproliferative neoplasms and JAK mutations, from biopsy and diagnosis to the use of JAK inhibition as treatment, as discussed by participants at virtual live events.
Ruxolitinib’s Role for Symptoms and Survival Benefit in Myelofibrosis
January 4th 2023During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.
Abbas Assesses the Use of Allogenic Transplant In MPNs
March 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with his fellow clinicians the use of allogeneic hematopoietic stem cell transplant in patients with myeloproliferative neoplasms and how ruxolitinib fits into their care.
Management of Ruxolitinib in MF Allows for Continued Survival Benefit
December 28th 2023In the second article of a 2-part series, Pankit Vachhani, MD, highlights the impact ruxolitinib has had, and continues, to have in treatment for patients with myelofibrosis and how physicians should manage this treatment for their patients.
Weighing the Triggers for Initiating JAK2 Inhibition Therapy in MF
March 23rd 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the triggers physicians need to consider when deciding to initiate therapy for patients with myelofibrosis in the first article of a 2-part series.